Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Phase I/II Study of Reduced Dose FCR (FCR-lite) in Combination with Lenalidomide Followed By Lenalidomide Maintenance (FCR 2 ) for Initial Therapy of CLL: Final Results and Long-Term Follow-up

Anthony R. Mato, MD, Andre Goy, MD, Tatyana A Feldman, MD, Joanna Rhodes, MD, Lori A. Leslie, MD, Mary Mrkulic, BS, Sabrina Kdiry, BSN, Kara Yannotti, BSN, Marisa Valentinetti, BSN, Stephen J. Schuster, MD, Jakub Svoboda, MD, Kenneth Foon, MD, Alan P Skarbnik, MD

Blood (2017) 130 (Supplement 1): 3012.

https://doi.org/10.1182/blood.V130.Suppl_1.3012.3012

Published: 2017

Journal Articles

Impact of Charlson Comorbidity Index (CCI) and Refining the MIPI Index in Mantle Cell Lymphoma (MCL)

Andre Goy, MD, Tommy Wu, Eric Hansen, Srikesh Arunajadai, Ewelina Protomastro, MS, Marisa Valentinetti, BSN, RN, Maureen Murphy, BSN, RN, Judith E Smith, BSN, RN, Ruth Pe Benito, Ali Hasan, Kiran Suryadevara, Tatyana Feldman, MD, Alan P Skarbnik, MD, Lori A. Leslie, MD, Scott D. Rowley, MD, Michele L. Donato, MD, Andrew L. Pecora, MD, Stuart L. Goldberg, MD

Blood (2016) 128 (22): 2973.

https://doi.org/10.1182/blood.V128.22.2973.2973

Published: 2016

Journal Articles

A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR 2 Regimen

Anthony R. Mato, MD MSCE, Kenneth A. Foon, MD, Tatyana Feldman, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Kar Fai Chow, MD, Marisa Valentinetti, BS, Mary Morin, BS, Kelly Azzollini, BS, Gabriella Magarelli, MS, Pritish K. Bhattacharyya, MD, Joshua Zenreich, BS, Christina Howlett, PharmD, BCOP, Lauren-Nicole Pascual, BS, Kara Yanotti, BSN, Sabrina Kdiry, BSN, David Porter, MD, Andre Goy, MD

Blood (2014) 124 (21): 4678.

https://doi.org/10.1182/blood.V124.21.4678.4678

Published: 2014

Journal Articles

Relapses of Diffuse Large B Cell Lymphoma in Rituximab Era Are Limited to the First Two Years after Frontline Therapy

Tatyana Feldman, MD, Larysa Gromko, MD, Ewelina A Protomastro, MS, Lina Starovoitova, BS, Anthony R. Mato, MD MSCE, Chad Glisch, Mona Sadekh, MD, Benjamin Schoener, MD, Susan Stives, APN, Marisa Valentinetti, RN, Mary Timberg, APN, Pritish K. Bhattacharyya, MD, Kar Fai Chow, MD, Xiao Yang, MD PhD, Alan P Skarbnik, MD, Andre Goy, MD MS

Blood (2014) 124 (21): 1307.

https://doi.org/10.1182/blood.V124.21.1307.1307

Published: 2014

Journal Articles

Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant

Tatyana Feldman, MD, Anthony R Mato, MD, Michele L. Donato, MD, Scott D Rowley, MD, Stuart L. Goldberg, MD, Carolanne Carini, RN, Marisa Valentinetti, RN, Judith Smith, RN, Gabriella Gadaleta, RN, APN-C, Coleen Bejot, MSN, NP-C, Susan Stives, APN, Mary Timberg, RN, MSN, OCN, NP-C, Ewelina A Protomastro, BA, Joshua R. Richter, MD, David H. Vesole, MD, PhD, Andrew L Pecora, MD, David S. Siegel, MD, PhD, Andre Goy, MD

Blood (2012) 120 (21): 3710.

https://doi.org/10.1182/blood.V120.21.3710.3710

Published: 2012

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A Phase I/II Study of Reduced Dose FCR (FCR-lite) in Combination with Lenalidomide Followed By Lenalidomide Maintenance (FCR 2 ) for Initial Therapy of CLL: Final Results and Long-Term Follow-up

Impact of Charlson Comorbidity Index (CCI) and Refining the MIPI Index in Mantle Cell Lymphoma (MCL)

A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR 2 Regimen

Relapses of Diffuse Large B Cell Lymphoma in Rituximab Era Are Limited to the First Two Years after Frontline Therapy

Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Update search

A Phase I/II Study of Reduced Dose FCR (FCR-lite) in Combination with Lenalidomide Followed By Lenalidomide Maintenance (FCR 2 ) for Initial Therapy of CLL: Final Results and Long-Term Follow-up

Impact of Charlson Comorbidity Index (CCI) and Refining the MIPI Index in Mantle Cell Lymphoma (MCL)

A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR 2 Regimen

Relapses of Diffuse Large B Cell Lymphoma in Rituximab Era Are Limited to the First Two Years after Frontline Therapy

Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only